Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Geographic Atrophy”

202 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 202 results

Not applicableUnknownNCT04469140
What this trial is testing

Non Exudative AMD Imaged With SS-OCT- Extension

Who this might be right for
Dry Macular Degeneration
Boston Image Reading Center 450
Large-scale testing (Phase 3)Study completedNCT04435366
What this trial is testing

Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

Who this might be right for
Geographic AtrophyMacular Degeneration
IVERIC bio, Inc. 448
Post-approval studies (Phase 4)Study completedNCT01775124
What this trial is testing

Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 332
Not applicableStudy completedNCT03333954
What this trial is testing

Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular Degeneration

Who this might be right for
Dry Age-related Macular Degeneration
Science Corporation 5
Testing effectiveness (Phase 2)Study completedNCT03815825
What this trial is testing

GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Who this might be right for
Macular DegenerationGeographic Atrophy
Ionis Pharmaceuticals, Inc. 332
Large-scale testing (Phase 3)Study completedNCT03525613
What this trial is testing

Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

Who this might be right for
Geographic Atrophy
Apellis Pharmaceuticals, Inc. 637
Not applicableStudy completedNCT01890187
What this trial is testing

Repeatability and Reproducibility of Cirrus HD-OCT Measurements of Illumination Areas Under the Retinal Pigment Epithelium

Who this might be right for
Advanced Dry AMD With Geographic Atrophy
Carl Zeiss Meditec, Inc. 85
Testing effectiveness (Phase 2)Study completedNCT02684578
What this trial is testing

Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD

Who this might be right for
Age-Related Macular DegenerationMacular Degeneration, Age-RelatedDry Macular Degeneration+1 more
University of California, San Francisco 66
Testing effectiveness (Phase 2)Study completedNCT03927690
What this trial is testing

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

Who this might be right for
Diabetic Macular Edema
Novartis Pharmaceuticals 91
Not applicableStudy completedNCT02332343
What this trial is testing

Sparing of the Fovea in Geographic Atrophy Progression

Who this might be right for
AtrophyGeographic AtrophyAge-related Macular Degeneration+1 more
University Hospital, Bonn 26
Testing effectiveness (Phase 2)Ended earlyNCT04437368
What this trial is testing

EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Who this might be right for
Dry Age-related Macular Degeneration
Gyroscope Therapeutics Limited 98
Testing effectiveness (Phase 2)Study completedNCT02288559
What this trial is testing

Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy

Who this might be right for
Geographic Atrophy
Genentech, Inc. 96
Post-approval studies (Phase 4)Study completedNCT04679935
What this trial is testing

Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration

Who this might be right for
Age-related Macular Degeneration
Novartis Pharmaceuticals 52
Not applicableLooking for participantsNCT06375239
What this trial is testing

Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration

Who this might be right for
Retinitis PigmentosaChoroideremiaStargardt Macular Dystrophy+4 more
Ray Therapeutics, Inc. 120
Testing effectiveness (Phase 2)Study completedNCT00658619
What this trial is testing

Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)

Who this might be right for
Macular Degeneration
Allergan 119
Large-scale testing (Phase 3)Study completedNCT04264819
What this trial is testing

Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration
Novartis Pharmaceuticals 295
Testing effectiveness (Phase 2)WithdrawnNCT04358471
What this trial is testing

Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA)

Who this might be right for
Dry Age-related Macular DegenerationGeographic AtrophyGene Therapy+1 more
Hemera Biosciences
Not applicableStudy completedNCT07428798
What this trial is testing

Subtenon PRP Injection for Geographic Atrophy in Dry Age-Related Macular Degeneration

Who this might be right for
Geographic AtrophyDry Age Related Macular Degeneration
Marmara University Pendik Training and Research Hospital 14
Testing effectiveness (Phase 2)WithdrawnNCT03446144
What this trial is testing

Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Who this might be right for
Geographic AtrophyAge Related Macular Degeneration
Ionis Pharmaceuticals, Inc.
Testing effectiveness (Phase 2)Study completedNCT02659098
What this trial is testing

Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy

Who this might be right for
Visual AcuityGeographic AtrophyMacular Degeneration
Janssen Research & Development, LLC 21
Load More Results